Healthcare

Cochlear makes cochlear implants, bone-conduction hearing devices and acoustic products, and provides services such as upgrades and sound-processor replacements. FY26 was a difficult year. Sales revenue was A$2,343.4 million, down 1% as reported but up 2% in constant currency (the second half grew 6% …

Sales were US$2,140.2 million, up 6.8%. Adjusted EBIT was US$321.9 million, up 14.1%, and the adjusted EBITMarginwas 15.0%, up 90 basis points. AdjustedEarnings Per Sharewere 148.6 US cents, up 18.5% on an organic constant-currency basis.

4DMedical develops software that analyses lung function from medical scans. Its technology, XV, produces measures of how air moves through the lungs, and the company sells it largely on aSoftware-as-a-Service (SaaS)basis, meaning subscription or per-use pricing rather than hardware sales. Its newer product, CT:VQ, …

On 12 October 2026, Racura Oncology Limited (ASX:RAC) announced that the HARNESS-1 Safety Review Committee had cleared the trial to progress from the initial 50 mg/m² RC220 dose to the next planned 100 mg/m² dose, administered in combination with osimertinib. The company said the …

For the year ended 30 June 2026, PolyNovo Limited (ASX:PNV) reported total revenue of AUD 150.0 million, up 16.1% from AUD 129.2 million in FY25. Commercial product sales increased 16.7% to AUD 138.4 million, or 21.3% on a constant-currency basis. The distinction matters because …

• Both market-sensitive announcements appeared on 15 October 2026, before subsequent substantial holder filings were submitted.

• The company generated AUD 2.0 million in positiveOperating Cash Flowduring the first quarter of FY27.